[an error occurred while processing this directive]
中华放射肿瘤学杂志
   2025年4月4日 星期五     首 页 |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告合作  |  学术影响  |  收录情况  |  联系我们  |  English
中华放射肿瘤学杂志  2020, Vol. 29 Issue (3): 179-183    DOI: 10.3760/cma.j.issn.1004-4221.2020.03.005
胸部肿瘤 最新目录| 下期目录| 过刊浏览| 高级检索 [an error occurred while processing this directive]|[an error occurred while processing this directive]
食管鳞癌新辅助治疗联合手术的复发模式分析
范诚诚, 冯卓, 葛红, 叶柯, 王浩, 郑晓丽, 张有改, 罗辉
郑州大学附属肿瘤医院 河南省肿瘤医院放疗科 450008
Analysis of recurrence pattern of neoadjuvant therapy combined with surgical treatment for esophageal squamous cell carcinoma
Fan Chengcheng, Feng Zhuo, Ge Hong, Ye Ke, Wang Hao, Zheng Xiaoli, Zhang Yougai, Luo Hui
Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      背景资料
摘要 目的 分析食管鳞癌新辅助治疗联合手术的复发模式及其影响复发的风险因素。方法 回顾分析2011-2015年间确诊的行新辅助治疗联合手术治疗及随访资料完整可分析的胸段食管鳞癌患者275例。分析新辅助联合手术治疗后复发的模式、复发时间、复发部位及影响复发的因素。Kaplan-Meier法计算复发率,Cox模型多因素分析。结果 中位随访时间32个月(3~84个月),术后首次复发中位时间为10.6个月(2.0~69.1个月)。全组患者1、2、3年复发率分别为32.0%、45.1%、52.3%。全组共出现152例(55.3%)复发,其中77例(50.6%)为局部区域复发(LRR),34例(23.4%)为远处转移(DM),33例患者(21.7%)为LRR+DM,8例(6.0%)患者复发部位不详。LRR者中淋巴结复发最常见(98例,89.1%),DM者中肺转移(33例,49.3%)、肝转移(16例,23.9%)、骨转移(14例,20.9%)和非区域淋巴结转移(14例,20.9%)较常见。多因素分析显示术后T分期(P=0.008)、N分期(P<0.001)及清扫淋巴结数目(P<0.001)是影响疗后复发的危险因素。结论 食管鳞癌新辅助治疗后仍有较高复发率,区域淋巴结为最常见复发部位。术后病理T、N分期及淋巴结清扫数目是影响疗后复发的危险因素。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
范诚诚
冯卓
葛红
叶柯
王浩
郑晓丽
张有改
罗辉
关键词 食管肿瘤/新辅助治疗复发模式因素分析    
AbstractObjective To evaluate the recurrence pattern and identify the risk factors of esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery.Methods Clinical data of 275 patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant therapy combined with surgery from December 2011 to December 2015 were retrospectively analyzed. The follow-up data of the enrolled patients were complete and analyzable. The recurrence pattern, recurrence time, recurrence location and influencing factors after neoadjuvant therapy in combination with surgery were analyzed. The recurrence rate was calculated by Kaplan-Meier method. The multivariate analysis was performed by Cox regression model. Results The median follow-up time was 32(3-84) months, and the median time of the first recurrence was 10.6(2.0-69.1) months. The 1-,2-and 3-year recurrence rates were 32.0%,45.1% and 52.3%, respectively. A total of 152 cases (55.3%) had recurrence. Among them,77 cases (50.6%) had local-regional recurrence (LRR),34 cases (23.4%) had distant metastasis (DM),33 cases (21.7%) had LRR+DM and 8 cases (6.0%) had recurrence in unknown site. Among the patients with LRR, lymph node recurrence was the most common (n=98,89.1%). For DM patients, lung metastasis (n=33,49.3%),liver metastasis (n=16,23.9%),bone metastasis (n=14,20.9%) and non-regional lymph node metastasis (n=14,20.9%) were commonly observed.The multivariate analysis showed that postoperative T stage (P=0.008), N stage (P<0.001) and the number of lymph node dissection (P<0.001) were the independent risk factors for recurrence after treatment.Conclusions The recurrence rate after neoadjuvant therapy remains relatively high for esophageal squamous cell carcinoma, and the regional lymph node is the most common site of recurrence. Postoperative pathological T staging, N staging and the number of lymph node dissection are the independent risk factors for recurrence after treatment.
Key wordsEsophageal neoplasm/neoadjuvant treatment    Recurrence pattern    Risk factor   
收稿日期: 2019-06-07     
基金资助:国家自然科学基金项目(81372436);河南省科技研发专项经费(182106000062);河南省医学科技攻关计划项目(2018020502)
通讯作者: 葛红,Email:gehong666@126.com   
引用本文:   
范诚诚,冯卓,葛红等. 食管鳞癌新辅助治疗联合手术的复发模式分析[J]. 中华放射肿瘤学杂志, 2020, 29(3): 179-183.
Fan Chengcheng,Feng Zhuo,Ge Hong et al. Analysis of recurrence pattern of neoadjuvant therapy combined with surgical treatment for esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 179-183.
链接本文:  
http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2020.03.005     或     http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2020/V29/I3/179
京公网安备11010502022167号
版权所有 © 2010《中华放射肿瘤学杂志》编辑部
地址:北京朝阳区潘学园南里17号 中国医学科学院肿瘤医院(100021)
电话:010-67700737,87788294 Email: cjron@cmaph.org
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:Support@magtech.com.cn